Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis
/in Breast Cancer, Colorectal Cancer, Glioblastoma, International Publications, Newcastle Disease Virus /von 2002-07-01 / Int. J. Oncol. 2002 Jul;21(1):85-93Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers
/in International Publications, Newcastle Disease Virus /von 2002-05-01 / J. Clin. Oncol. 2002 May;20(9):2251-66Heat shock and heat shock protein 70i enhance the oncolytic effect of replicative adenovirus
/in Hyperthermia, International Publications, Newcastle Disease Virus /von 2001-12-01 / Cancer Res. 2001 Dec;61(23):8361-5Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration
/in International Publications, Newcastle Disease Virus /von 2001-10-22 / Cancer Lett. 2001 Oct;172(1):27-36Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects
/in International Publications, Newcastle Disease Virus /von 2001-05-01 / Int. J. Oncol. 2001 May;18(5):945-52Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 2001-05-01 / J. Neurooncol. 2001 May;53(1):39-46Newcastle disease virus (NDV): brief history of its oncolytic strains
/in International Publications, Newcastle Disease Virus /von 2000-02-01 / J. Clin. Virol. 2000 Feb;16(1):1-15Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 1999-05-05 / JAMA 1999 May;281(17):1588-9Tumor stimulator cell modification by infection with Newcastle Disease Virus: analysis of effects and mechanism in MLTC-CML cultures
/in International Publications, Newcastle Disease Virus /von 1999-02-01 / Int. J. Oncol. 1999 Feb;14(2):205-15
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- From Localized Mild Hyperthermia to Improved Tumor Oxygenation: Physiological Mechanisms Critically Involved in Oncologic Thermo-Radio-Immunotherapy
- Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
- Immunotherapy in breast cancer: an overview of current strategies and perspectives